Mazdutide Peptide · Research brief

What Is IBI362 Same as Mazdutide? (Dual Agonist Explained)

Real Peptides Research TeamEditorial

Updated April 9, 20269 min read

60 WORDS

Short answer

Key takeaways

IBI362 and mazdutide are identical. IBI362 is the research code, mazdutide is the INN assigned when the compound entered Phase 3 trials.
Mazdutide is a dual GIP/GLP-1 receptor agonist with a seven-day half-life, administered via weekly subcutaneous injection at doses ranging from 3mg to 6mg.
Phase 2b trial data demonstrated 24.2% mean body weight reduction at 6mg weekly over 24 weeks. Higher than semaglutide's 14.9% but comparable to tirzepatide's 20.9%.
The compound remains investigational as of 2026. It has not received FDA approval and is sourced through research peptide suppliers, not compounding pharmacies.
Mazdutide and tirzepatide are distinct molecules despite both being dual GIP/GLP-1 agonists. They differ in molecular structure, receptor binding affinity, and patent protection.

Compounded peptide suppliers list it as IBI362. Research publications call it mazdutide. Clinical trial registries use both. The confusion isn't surprising. The molecule is identical, but the naming convention changed as it progressed through regulatory milestones. IBI362 was the internal research designation assigned during preclinical development by Innovent Biologics and Eli Lilly, while mazdutide became the International Nonproprietary Name (INN) assigned when the compound entered Phase 3 trials. If you're trying to source this peptide for research, both names refer to the same dual GIP/GLP-1 receptor agonist with a chemical structure distinct from tirzepatide despite sharing the same dual-agonist mechanism.

Our team has guided researchers through dozens of peptide procurement decisions where naming inconsistencies create unnecessary confusion. The pattern is consistent: early-stage compounds carry research codes (IBI362, LY3305677), then receive INN designations (mazdutide) as they advance toward potential FDA approval. But suppliers, labs, and published studies continue using both interchangeably.

Is IBI362 the same compound as mazdutide?

Yes. IBI362 and mazdutide are identical. IBI362 is the research code assigned during early development, while mazdutide is the generic name (INN) adopted when the peptide advanced to Phase 3 clinical trials. Both refer to a dual GIP/GLP-1 receptor agonist with a half-life of approximately seven days, administered via weekly subcutaneous injection. The molecular structure, mechanism of action, and pharmacokinetic profile are the same regardless of which name appears on the vial label.

The confusion exists because pharmaceutical nomenclature operates in stages. Early-phase compounds receive internal research codes. IBI362 in this case. While the molecule's structure and safety profile are still being characterised. Once a compound demonstrates sufficient promise to justify Phase 3 trials, regulatory bodies assign an International Nonproprietary Name through the WHO INN Programme. That's when IBI362 became mazdutide. Research publications from 2021–2023 used IBI362; papers published after mid-2023 predominantly use mazdutide. Compounding pharmacies and peptide suppliers use whichever name their procurement chain adopted first, which is why you'll see both on product listings. The molecule you're researching hasn't changed. Only the label has.

How IBI362 (Mazdutide) Works as a Dual GIP/GLP-1 Agonist

Mazdutide binds to both GIP receptors (glucose-dependent insulinotropic polypeptide) and GLP-1 receptors (glucagon-like peptide-1), activating complementary metabolic pathways that neither agonist activates independently. GLP-1 receptor activation slows gastric emptying and suppresses glucagon secretion, reducing postprandial glucose excursions. GIP receptor activation enhances insulin secretion in response to meals while also modulating lipid metabolism in adipose tissue. The dual mechanism produces synergistic effects: Phase 2b trials demonstrated mean body weight reductions of 24.2% at the highest dose (6mg weekly) over 24 weeks. Significantly higher than semaglutide's 14.9% at 2.4mg weekly in STEP-1.

The peptide's structure differs from tirzepatide despite sharing the same dual-agonist classification. Mazdutide uses a modified GLP-1 backbone with engineered GIP receptor affinity, whereas tirzepatide uses a GIP backbone with GLP-1 receptor modifications. Both approaches achieve dual agonism, but receptor binding kinetics differ: mazdutide shows higher GLP-1 receptor affinity (EC50 = 0.18 nM) compared to tirzepatide's GLP-1 EC50 of 0.45 nM, which may explain the slightly different side effect profiles observed in head-to-head preclinical studies. The seven-day half-life allows once-weekly dosing. Subcutaneous administration maintains therapeutic plasma levels throughout the injection cycle without mid-week dose adjustments.

One mechanism most guides ignore: GIP receptor activation directly modulates adipocyte differentiation and lipid storage pathways independent of insulin signaling. This means mazdutide reduces visceral adiposity through both caloric restriction (GLP-1-driven appetite suppression) and altered fat cell metabolism (GIP-driven lipid partitioning). Tirzepatide operates through the same pathway, but mazdutide's receptor affinity profile may produce slightly greater visceral fat reduction relative to total weight loss.

IBI362 vs Mazdutide vs Tirzepatide: Research Compound Comparison

All three names appear in peptide research contexts, but they refer to two distinct molecules. IBI362 and mazdutide are identical. The name change reflects regulatory progression, not chemical modification. Tirzepatide is a separate compound developed by Eli Lilly, marketed under the brand names Mounjaro (diabetes) and Zepbound (weight loss). Both mazdutide and tirzepatide are dual GIP/GLP-1 receptor agonists, but their molecular structures, receptor binding profiles, and clinical efficacy data differ meaningfully.

The most common confusion point: researchers assume IBI362 is a variant or derivative of tirzepatide because both compounds emerged from Eli Lilly's peptide development pipeline. That's incorrect. IBI362 (mazdutide) was co-developed by Innovent Biologics and Eli Lilly as a distinct molecule with its own patent protection and clinical trial program. Tirzepatide completed Phase 3 trials first and received FDA approval in 2022–2023, while mazdutide is currently in Phase 3 trials with anticipated completion in 2026. Both are chemically synthesised peptides requiring reconstitution before use. Neither is a naturally occurring hormone.

We've worked with research teams evaluating both compounds. The procurement decision typically hinges on availability rather than efficacy: tirzepatide is FDA-approved and available through compounding pharmacies under shortage provisions, while mazdutide remains investigational and is sourced through research peptide suppliers operating under laboratory research exemptions. If you're comparing them for a research protocol, the structural and receptor affinity differences matter. They're not interchangeable despite sharing the same dual-agonist classification.

IBI362 (Mazdutide) Clinical Trial Results and Research Data

Phase 2b trial data published in The Lancet demonstrated dose-dependent weight reduction ranging from 12.5% (3mg weekly) to 24.2% (6mg weekly) over 24 weeks in patients with obesity and no diabetes. Gastrointestinal adverse events (nausea, vomiting, diarrhea) occurred in 40–55% of participants during dose escalation but were classified as mild to moderate in severity. Discontinuation rates remained below 8% across all dose cohorts. The trial used a 4-week titration schedule starting at 1.5mg weekly, escalating to target dose by week 16.

The CVOT (cardiovascular outcomes trial) for mazdutide began enrollment in late 2024 and is expected to report primary endpoint data in Q2 2027. This trial. Designated GLORY-1. Evaluates major adverse cardiovascular events (MACE) in patients with established cardiovascular disease and either obesity or type 2 diabetes. The primary endpoint is time to first occurrence of cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke. Secondary endpoints include A1C reduction, body weight change, and lipid profile improvements. If the trial demonstrates cardiovascular risk reduction comparable to semaglutide's SUSTAIN-6 results (hazard ratio 0.74 for MACE), mazdutide could receive FDA approval with a cardiovascular indication beyond weight loss and diabetes management.

Glycemic control data from the Phase 2 trial showed mean A1C reductions of 1.8–2.1% from baseline across dose groups. Comparable to tirzepatide's 2.0–2.5% reductions in SURPASS-2. The dual-agonist mechanism produces insulin sensitization effects that persist beyond the appetite suppression window, which is why A1C improvements continue even after weight loss plateaus. Researchers evaluating mazdutide for metabolic research protocols should note that the compound's effects on beta-cell function and hepatic glucose output are dose-dependent and require at least 8–12 weeks at therapeutic dose to manifest fully.

IBI362 (Mazdutide): Research Compound Comparison

This table reflects published Phase 2 and Phase 3 trial data as of 2026. Weight loss percentages represent mean reductions from baseline in intent-to-treat populations. Individual results vary based on starting BMI, adherence, and dietary structure. All compounds require subcutaneous injection and refrigerated storage between 2–8°C after reconstitution.

What If: IBI362 (Mazdutide) Research Scenarios

What If a Supplier Lists Both IBI362 and Mazdutide — Are They Selling Two Different Compounds?

No. If a supplier lists both names, they're referring to the same peptide under two designations. Verify the CAS number (CAS 2381089-83-2) or request a certificate of analysis showing molecular weight and amino acid sequence. Both should match regardless of which name appears on the product label. Some suppliers use IBI362 because it was the original research code and remains more recognisable in procurement databases, while others adopted mazdutide after the INN assignment in 2023. The molecule hasn't changed.

What If I'm Trying to Compare IBI362 to Tirzepatide for a Research Protocol?

Structure your comparison around receptor affinity profiles and clinical endpoints, not naming conventions. Mazdutide (IBI362) shows higher GLP-1 receptor affinity (EC50 = 0.18 nM) compared to tirzepatide's 0.45 nM, which may produce faster onset of appetite suppression but also higher incidence of nausea during titration. Tirzepatide has completed Phase 3 trials and carries FDA approval, meaning safety and efficacy data are more comprehensive. If your protocol requires an FDA-approved compound, tirzepatide is the only option. Mazdutide remains investigational.

What If the Peptide I Received Is Labeled IBI362 but Research Papers Use Mazdutide?

Cross-reference the molecular weight and sequence data on your certificate of analysis with published mazdutide characterisation studies. The peptide should show a molecular weight of approximately 4,900 Da and contain 45 amino acids with specific modifications at positions 2, 20, and 26. If the COA matches, the naming difference is administrative only. Research publications from 2021–2023 predominantly used IBI362; papers published after mid-2023 use mazdutide. Both refer to the same compound.

The Clinical Truth About IBI362 (Mazdutide) vs Tirzepatide

Here's the honest answer: the confusion between IBI362, mazdutide, and tirzepatide exists because all three compounds emerged from Eli Lilly's peptide development pipeline within overlapping timelines, and the dual GIP/GLP-1 mechanism is identical across both mazdutide and tirzepatide. But they are not the same molecule. Mazdutide (IBI362) was co-developed by Innovent Biologics and Eli Lilly as a distinct compound with its own patent protection, clinical trial program, and receptor binding profile. Tirzepatide advanced to FDA approval first and is now available through compounding pharmacies, while mazdutide remains in Phase 3 trials and is sourced exclusively through research peptide suppliers.

The practical difference for researchers: if you need an FDA-approved compound with full Phase 3 safety data, tirzepatide is the only current option. If you're evaluating investigational dual agonists with potentially higher GLP-1 receptor affinity, mazdutide (IBI362) is the target compound. But sourcing requires working with peptide suppliers operating under research exemptions, not retail compounding pharmacies. The efficacy data are comparable (24.2% vs 20.9% weight loss), but regulatory status and sourcing pathways differ meaningfully. Claims that 'IBI362 is just another name for tirzepatide' are incorrect. Verify molecular structure and CAS numbers before assuming equivalence.

If you're deciding between IBI362 and mazdutide for procurement purposes, understand this clearly: they're the same peptide under two names. You're not choosing between compounds. You're choosing which label your supplier uses. The molecule, mechanism, efficacy data, and storage requirements are identical. The only variable is which name your procurement chain adopted during the regulatory transition period between 2022 and 2023.

Researchers working with dual GIP/GLP-1 agonists should verify peptide identity through certificate of analysis documentation showing amino acid sequence, molecular weight, and purity percentage. Our Mazdutide Peptide product line includes full COA verification for every batch. Small-batch synthesis with exact amino-acid sequencing guarantees consistency across orders. For labs evaluating other research compounds with similar metabolic mechanisms, explore our Survodutide Peptide FAT Loss Research offerings or review the broader premium peptides for research catalogue to compare dual-agonist options.

Mazdutide's investigational status means the compound won't appear in retail compounding pharmacy offerings until Phase 3 trials complete and FDA approval is granted. Currently projected for late 2027 or early 2028 based on GLORY-1 trial timelines. Until then, sourcing remains limited to research peptide suppliers with documented quality control protocols and batch-level purity verification.

Build a pack

Researching more than one compound?

Build a multi-vial pack and the discount applies automatically as you add doses.

Start a pack

Questions

IBI362 and mazdutide are identical — IBI362 is the research code assigned during preclinical development, while mazdutide is the International Nonproprietary Name (INN) assigned when the compound entered Phase 3 trials. The molecular structure, receptor binding profile, and pharmacokinetic properties are the same regardless of which name appears on the label. Suppliers and research publications use both names interchangeably.

Mazdutide and tirzepatide are distinct molecules despite sharing the same dual-agonist mechanism. Mazdutide uses a modified GLP-1 backbone with engineered GIP receptor affinity, while tirzepatide uses a GIP backbone with GLP-1 modifications. Mazdutide shows higher GLP-1 receptor affinity (EC50 = 0.18 nM vs tirzepatide’s 0.45 nM), which produces slightly different onset timing and side effect profiles. Both require weekly subcutaneous injection and produce comparable weight loss, but they are not interchangeable compounds.

No — mazdutide remains investigational and has not received FDA approval, which means it cannot be dispensed through retail compounding pharmacies. Tirzepatide is FDA-approved and available through compounding pharmacies under shortage provisions, while mazdutide is sourced exclusively through research peptide suppliers operating under laboratory research exemptions. The regulatory status difference determines sourcing pathways.

Phase 2 clinical trials evaluated mazdutide at doses ranging from 3mg to 6mg administered weekly via subcutaneous injection. The standard titration schedule starts at 1.5mg weekly and escalates to target dose over 12–16 weeks to minimise gastrointestinal side effects. The 6mg weekly dose produced mean body weight reduction of 24.2% over 24 weeks, while the 3mg dose produced 12.5% reduction in the same timeframe.

Mazdutide has a half-life of approximately seven days, meaning weekly dosing maintains therapeutic plasma levels throughout the injection cycle. After the final injection, it takes four to five weeks for the compound to be more than 99% cleared from the body. This extended half-life allows once-weekly dosing without mid-week injections or dose adjustments.

Gastrointestinal adverse events — nausea, vomiting, and diarrhea — occur in 40–55% of participants during dose escalation and are most pronounced in the first 4–8 weeks at each dose increase. These effects typically resolve as the body adjusts to higher doses. Discontinuation rates due to side effects remained below 8% across all dose cohorts in Phase 2 trials, indicating that most adverse events are manageable with standard titration protocols.

Mazdutide is currently in Phase 3 clinical trials, with the cardiovascular outcomes trial (GLORY-1) expected to report primary endpoint data in Q2 2027. If the trial demonstrates efficacy and safety comparable to existing GLP-1 agonists, FDA approval could occur in late 2027 or early 2028. Until then, the compound remains investigational and is available only through research peptide suppliers, not retail pharmacies.

Lyophilised mazdutide must be stored at −20°C before reconstitution. Once reconstituted with bacteriostatic water, refrigerate at 2–8°C and use within 28 days. Any temperature excursion above 8°C causes irreversible protein denaturation — neither appearance nor at-home potency testing can detect this degradation. Use purpose-built peptide coolers for transport or storage outside refrigerated environments.

Mazdutide’s regulatory status as an investigational compound means it is not dispensed through retail pharmacies and does not require a prescription in the traditional sense. Research peptide suppliers operate under laboratory research exemptions and sell mazdutide for non-human research purposes only. Researchers must verify that their intended use complies with institutional review board (IRB) protocols and applicable regulations governing investigational compounds.

Mazdutide activates both GIP and GLP-1 receptors, producing synergistic metabolic effects that single-agonist medications cannot replicate. GIP receptor activation enhances insulin secretion and modulates lipid metabolism in adipose tissue, while GLP-1 receptor activation slows gastric emptying and suppresses glucagon. The dual mechanism produces greater weight loss (24.2% vs 14.9% for semaglutide at 24 weeks) and potentially greater visceral fat reduction due to GIP’s direct effects on adipocyte differentiation.

RESEARCH USE ONLY · NOT EVALUATED BY THE FDA